Evaluation of recombinant α-galactosidase a therapy for amelioration of the cardiovascular manifestations of fabry disease an important role for endomyocardial biopsy

Circulation

Volumn 119, Issue 19, 2009, Pages 2539-2541

  Buja, L Maximilian ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Arteriosclerosis; Coronary disease; Ediorials; Gene therapy

Indexed keywords

ALPHA GALACTOSIDASE; BIOLOGICAL MARKER; GLOBOTRIAOSYLCERAMIDE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; RECOMBINANT ALPHA GALACTOSIDASE A; UNCLASSIFIED DRUG; CERAMIDE TRIHEXOSIDE; RECOMBINANT PROTEIN;

AMYLOIDOSIS; ATHEROSCLEROSIS; CAPILLARY ENDOTHELIUM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; EDITORIAL; ELECTRON MICROSCOPY; ENDOTHELIAL DYSFUNCTION; ENZYME METABOLISM; ENZYME REPLACEMENT; EVALUATION; FABRY DISEASE; HEART GRAFT; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART RIGHT VENTRICLE; HISTOLOGY; HUMAN; HYPERTENSION; LEUKOCYTE ACTIVATION; MICROVASCULATURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOSIS; VASCULAR DISEASE; BIOPSY; CAPILLARY; CELL INCLUSION; CHEMISTRY; ENDOCARDIUM; METABOLISM; MICROCIRCULATION; MULTICENTER STUDY; NOTE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; ULTRASTRUCTURE; VASCULAR ENDOTHELIUM;

ALPHA-GALACTOSIDASE; BIOPSY; CAPILLARIES; CLINICAL TRIALS, PHASE III AS TOPIC; CORONARY DISEASE; ENDOCARDIUM; ENDOTHELIUM, VASCULAR; FABRY DISEASE; HUMANS; INCLUSION BODIES; MICROCIRCULATION; MULTICENTER STUDIES AS TOPIC; MYOCYTES, CARDIAC; RECOMBINANT PROTEINS; TRIHEXOSYLCERAMIDES;

EID: 66349092464     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.861534     Document Type: Editorial

References (31)

1. Pierre-Louis B, Kumar A, Frishman WH. Fabry disease: cardiac manifestations and therapeutic options. Cardiol Rev. 2209;17:31-35.
2. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cells types after enzyme replacement therapy. Kidney Int. 2002;62:1933-1946.
3. Thurberg BL, H. Byers HR, Granter SR, Phelps RG, Gordon RE, O'Callaghan M. Monitoring the three year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Derm. 2004;122:900-908.
4. Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan M. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation. 2009;119:2561-2567.
5. Buja LM, Willerson JT. The role of coronary artery lesions in ischemic heart disease: insights from recent clinicopathologic, coronary arterio-graphic, and experimental studies. Human Pathol. 1987;18:451-461.
6. Fishbein MC. The vulnerable and unstable atherosclerotic plaque. Cardiovasc Pathol. October 1, 2008. DOI: 10.10167j.carpath.2008.08.004. Available at: http://www.sciencedirect.com/science?-ob=ArticleURL&-udi= B6T13-4TK2PFG-5&-user=10&-rdoc=1&-fmt=&-orig=search&-sort= d&view=c&-acct=C000050221&-version=l&-urlVersion=0&-userid= 10&md5=13a33b94044ed4613a3553ec08eacae6. Accessed April 30, 2009.
7. Rose A. Diseases of the small coronary arteries. In: Silver MD, ed. Cardiovascular Pathology, 2nd ed. New York, NY: Churchill Livingstone; 1991:565-593.
8. Waller BF. Nonatherosclerotic coronary heart disease. In: Fuster V, O'Rourke RA, Walsh RA, Poole-Wilson P, eds. Hurst's The Heart, 12th ed. New York, NY: McGraw Hill; 2008:1277-1310.
9. Di Monaco A, Bruno I, Sestito A, Lamendola P, Barone L, Bagnato A, Nerla R, Pisanello C, Giordano A, Lanza GA, Crea F. Cardiac adrenergic nerve function and microvascular dysfunction in patients with cardiac syndrome X. Heart. 2009;95:550-554.
10. Yagishita A, Tanimoto S, Tanabe K, Isogawa A, Taniguchi M, Shiba T, Hara K. Cardiac amyloidosis presumptively diagnosed as cardiac syndrome X. Circ J. Dec 27, 2008. DOI: 10.1253/circj.CJ-08-0353. Available at: http://www.jstage.jst.go.jp/article/circj/advpub/0/advpub-0812260217/-article. Accessed April 30, 2009.
11. Fisher EA, Desnick RJ, Gordon RE, Eng CM, Griepp R, Goldman ME. Fabry disease: an unusual cause of severe coronary disease in a young man. Ann Intern Med. 1992; 117:221-223.
12. Elleder M. Sequelae of storage in Fabry disease: pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl. 2003;443:46-53.
13. Strujid BJ, Jeren T. Fabry disease: a diagnostic and therapeutic problem. Ren Fail. 2005;27:783-786.
14. Schiffmann R, Ries M, Askari H, Rapkiewicz A, Abu-Asab M, Tsokos M, Quezado M. Pathological findings in a patient with Fabry disease who died after 1.5 years of enzyme replacement. Virchows Arch. 2006;448: 337-343.
15. Chimenti C, Morgante E, Critelli G, Russo M, Frustaci A. Coronary artery bypass grafting for Fabry's disease: veins more suitable than arteries? Hum Pathol. 2007;38:1864-1867.
16. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006; 1:297-329.
17. Hansson GK. Atherosclerosis - An immune disease. The Anitschkow Lecture 2007. Atherosclerosis. 2009;202:2-10.
18. Tsimikas S, Aikawa M, Miller FJ Jr, Miller ER, Torzewski M, Lentz SR, Bergmark C, Heistad DD, Libby P, Witztum JL. Increased plasma oxidized phospholipid: apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: A potential biomarker of early atherosclerosis regression. Arterioscler Thromb Vasc Biol. 2007;27:175-181.
19. Billingham ME. Role of endomyocardial biopsy in diagnosis and treatment of heart disease. In: Silver MD, ed. Cardiovascular Pathology. 2nd ed. New York, NY: Churchill Livingstone; 1991:1465-1486.
20. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M. Kiihl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50:1914-1931.
21. Winters GL, McManus BM. Myocarditis. In: Silver MD, Gotlieb AI, Schoen FJ, eds. Cardiovascular Pathology, 3rd ed. New York, NY: Churchill Livingstone; 2001:256-284.
22. Maron BJ, Towbin J, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006; 113: 1807-1816.
23. Ellis CR, Di Salvo T. Myocarditis: basic and clinical aspects. Cardiol Rev. 2007;15:170-177.
24. Holzmann M, Nicko A, Kühl U, Noutsias M, Poller W, Hoffmann W, Morguet A, Witzenbichler B, Tschöpe C, Schultheiss H-P, Pauschinger M. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation. 2008;118: 1722-1728.
25. Caforio ALP, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, Ramondo A, Carturan E, Iliceto S, Thiene G, Daliento L. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J. 2007;28: 1326-1333.
26. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müllelr T, Lindinger A, Böhm M. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118:639-648.
27. Kühl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M, Poller W, Schultheiss H-P. Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol. 2008; 80:1243-1251.
28. Tan CD, Balwin WM III, Rodriguez ER. Update on cardiac transplantation pathology. Arch Pathol Lab Med. 2007;131:1169-1191.
29. Bayliss J, Maguire JA, Bailey M, Leet A, Kaye D, Richardson M, Bergin PJ, Dowling J, Thomson NM, Stein AN. Increased vascular endothelial growth factor mRNA in endomyocardial biopsies from allografts demonstrating severe acute rejection: a longitudinal study. Transpl Immunol. 2008;18:264-274.
30. Zakliczynski M, Nozynski J, Knoecka-Mrowka D, Pyka L, Trybunia D, Swierad M, Maruszewski M, Zembala M. Allograft vasculopathy: quilty effect correlates with biopsy-proven acute cellular rejection but does not predict transplanted heart coronary artery vasculopathy. J Heart Lung Transplant. 2009;28:255-259.
31. Yamani MH, Taylor DO, Rodriguez ER, Cook DJ, Zhou L, Smedira N, Starling RC. Transplant vasculopathy is associated with increased allomap gene expression score. J Heart Lung Transplant. 2007;26: 403-406.3